Disruption of ccl2 in mesenchymal stem cells as an anti-tumor approach against prostate cancer

HIGHLIGHTS

• who: Quoc Thang Bui et al. from the Taipei University, Taipei, Taiwan have published the research work: Disruption of CCL2 in Mesenchymal Stem Cells as an Anti-Tumor Approach against Prostate Cancer, in the Journal: Cancers 2023, 15, x FOR PEER REVIEW of 16/Oct/2018
• what: Genetically engineered MSCs with CCL2 knockout can enhance the anti-tumor effect in an immune-competent syngeneic mouse model of prostate cancer.
• how: To secure the abundance and consistency of MSCs for further investigation the authors used commercially available mouse bone marrow-derived MSCs and confirmed . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.